Immuron Limited (IMRN) |
2.78 0.03 (1.09%) 03-27 16:00 |
Open: | 2.77 |
High: | 2.8 |
Low: | 2.6801 |
Volume: | 13,772 |
Market Cap: | 16(M) |
PE Ratio: | -6.32 |
Exchange: | NASDAQ Capital Market |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 5.96 |
Resistance 1: | 4.31 |
Pivot price: | 2.95 |
Support 1: | 1.65 |
Support 2: | 1.37 |
52w High: | 5.96 |
52w Low: | 1.481 |
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.
EPS | -0.450 |
Book Value | 0.080 |
PEG Ratio | 0.00 |
Gross Profit | 0.000 |
Profit Margin (%) | -108.52 |
Operating Margin (%) | -78.73 |
Return on Assets (ttm) | -9.9 |
Return on Equity (ttm) | -20.0 |
Sun, 24 Mar 2024
Immuron Pulls Plug On COVID-19 Treatment Hopeful, Citing Changing Landscape - Yahoo News Canada
Thu, 21 Mar 2024
Immuron to join exclusive list of ASX biotechs says Pitt Street Research - Proactive Investors USA
Thu, 21 Mar 2024
Immuron Pulls Plug On COVID-19 Treatment Hopeful, Citing Changing Landscape - AOL
Thu, 07 Mar 2024
Stocks of the Hour: Dotz Nano, Immuron, Avecho Biotechnology - ShareCafe
Thu, 07 Mar 2024
Immuron doubles on promising Travelan® Phase 2 results, advancing to Phase 3 trials in US - Proactive Investors Australia
Thu, 07 Mar 2024
Immuron stock surges after mid-stage data for Travelan - Seeking Alpha
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |